Clinical, kinematic and electrophysiological characterization of patients with Progressive Supranuclear Palsy and pharmacological modulation with Venlafaxine
Phase 2
- Conditions
- G23.1Progressive supranuclear ophthalmoplegia [Steele-Richardson-Olszewski]
- Registration Number
- DRKS00025481
- Lead Sponsor
- Deutsche Forschungsgemeinschaft (DFG) - SFB 936 - 178316478 - C8
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 35
Inclusion Criteria
Sporadic onset; age at symptom onset 40 years or older; gradual progression of symptoms; signed consent form
Exclusion Criteria
Patient lacks capacity to consent; age <40 or >80 years; patient affected by diabetes mellitus, COPD, or immunosuppression (to a clinically relevant degree)
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change in neuropsychiatric/neurocognitive symtoms captured by Trail Making Test (TMT), Starkstein Apathy Scale (SAS) and Geriatric Depression Scale (GDS) after at least 4 weeks of venlafaxine administration, compared to the assessment before start of venlafaxine administration.
- Secondary Outcome Measures
Name Time Method Parameter in objective gait analysis, pupillometry, EEG, as well as changes in the PSP-Rating scale (PSP-RS).<br>Changes in PSP stage, PSP-Clinical Deficits Scale (PSP-CDS), Montreal Cognitive Assessment (MoCA-Test), Three-clap test, Luria-Sequence and Verbal Fluency from the Frontal Assessment Battery (FAB), Schwab and England Activities of Daily Living (SEADL), Clinical Global Impression-Severity Scale (CGI-s), PSP-Quality of Life Scale (PSP-QoL) and Munich Dyphagia Test (MDT).<br>All parameter before and after venlafaxine administration of at least 4 weeks.